← Back to screener

NOVAVAX INC NVAX

Rank #1802 · Nasdaq · $1.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
41.8
P/E
-3.0
P/B
-2.61
ROE
86.0%
Op. Margin
-57.6%
Debt Ratio
-344%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -3.0x, P/B -2.61x. Ranks in the top 97% of the universe.

Profitability ★★★☆☆
Average

ROE 86.0%. Ranks in the top 46% of the universe.

Safety ★★★★★
Excellent

Debt ratio -344%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 50.4% year over year. Ranks in the top 97% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–37
2012$0.0B$-0.0B$-0.0B$0.1B-11222.718
2013$0.0B$-0.0B$-0.0B$0.1B-146.937
2014$0.0B$-0.0B$-0.0B$0.1B-134.459
2015$0.0B$-0.1B$-0.1B$0.1B-250.758
2016$0.0B$-0.1B$-0.1B$0.2B-273.046
2017$0.0B$-0.2B$-0.2B$0.2B-433.8174
2018$0.0B$-0.3B$-0.3B$0.3B-1752.8138
2019$0.0B$-0.2B$-0.2B$-0.0B-550.8-6778
2020$0.0B$-0.2B$-0.2B$-0.1B-507.2-353
2021$0.0B$-0.1B$-0.1B$-0.2B-646.1-569
2022$0.5B$-0.4B$-0.4B$-0.2B-87.6-1574
2023$1.1B$-1.7B$-1.7B$0.6B-147.1461
2024$2.0B$-0.6B$-0.7B$-0.4B-32.5-715
2025$1.0B$-0.6B$-0.5B$-0.6B-57.6-344

← See the full screener